Lymphoma Clinical Trials in Philadelphia

Showing 221-240 of 518 trials

The clonoSEQ® Watch Registry

NCT04545333

This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.

Acute Lymphoblastic Leukemia, Adult B-CellChronic Lymphocytic LeukemiaMultiple Myeloma+1 more

Adaptive Biotechnologies465 participantsStarted Oct 2020

Stanford, California, United States • Washington D.C., District of Columbia, United States • Fort Lauderdale, Florida, United States +11 more locations

COMPLETEDPhase 2< 1 mile

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

NCT02445248

This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.

Diffuse Large B-cell Lymphoma (DLBCL)

Novartis Pharmaceuticals115 participantsStarted Jul 2015

San Francisco, California, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +23 more locations

The clonoSEQ® Watch Registry

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Lymphoma Trials in Other Cities

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Phase I/II Study of Avelumab in Pediatric Cancer Participants

Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Other Conditions in Philadelphia